AMO Pharma (United Kingdom)

Recent papers from AMO Pharma (United Kingdom)

1. Population Pharmacokinetics of Tideglusib in Congenital and Childhood Myotonic Dystrophy Type 1: Influence of Demographic and Clinical Factors on Systemic ExposurePharmaceutics · 2025
2. An open-label study evaluating the safety and efficacy of AMO-01 for the treatment of seizures in Phelan-McDermid syndromeHuman Genetics and Genomics Advances · 2024
3. Respiratory Effects of the Atypical Tricyclic Antidepressant Tianeptine in Human Models of Opioid-induced Respiratory DepressionAnesthesiology · 2022
4. Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In VivoJournal of Virology · 2021
5. ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human studyBritish Journal of Clinical Pharmacology · 2021
6. Pharmacological profile and clinical efficacy of anamorelin HCl (ADLUMIZ®Tablets), the first orally available drug for cancer cachexia with ghrelin-like action in JapanFolia Pharmacologica Japonica · 2021
7. A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)Pediatric Neurology · 2020
8. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X SyndromePediatric Neurology · 2020
9. The Position of Neuromuscular Patients in Shared Decision Making. Report from the 235th ENMC Workshop: Milan, Italy, January 19-20, 2018Journal of Neuromuscular Diseases · 2019
10. Can Target Costing and Whole Life Costing be Applied in the Construction Industry?: Evidence from Two Case StudiesBritish Journal of Management · 2000